US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

COYA THERAPEUTICS INC

6.28

-0.3100-4.70%

Post-market: 6.280.00000.00%16:09 EDT

Volume:40.41K

Turnover:255.53K

Market Cap:105.03M

PE:-6.43

High:6.64

Open:6.64

Low:6.20

Close:6.59

Loading ...

Overview Company News Filings

Coya Therapeutics Is Maintained at Buy by D. Boral Capital

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study With Low-Dose Il-2 and Ctla4-Ig Combination Treatment in Five Patients With Mild to Moderate Frontotemporal Dementia

THOMSON REUTERS

Coya Therapeutics Inc - Study Shows Significant Increase in Treg Numbers and Function

THOMSON REUTERS

Coya Therapeutics Inc - Ftd Patients Show Minimal to No Cognitive Decline in Study

THOMSON REUTERS

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia

Wall Street Analysts See a 144.73% Upside in Coya Therapeutics, Inc. (COYA): Can the Stock Really Move This High?

Coya Therapeutics announces publication of study results on COYA 303

Coya Therapeutics Announces Publication of Glp-1/Ld Il-2 Combination Biologic (Coya 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)

THOMSON REUTERS

Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)

BRIEF-Atea Pharmaceuticals Appoints Howard H. Berman To Board Of Directors And Announces Share Repurchase Program

Atea Pharmaceuticals Inc: Authorized Repurchase of up to $25 Mln of Company's Common Stock

THOMSON REUTERS

Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

THOMSON REUTERS

Press Release: Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

Is Coya Therapeutics (COYA) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?

Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025

What Makes Coya Therapeutics, Inc. (COYA) a New Buy Stock

Are Medical Stocks Lagging Auna S.A. (AUNA) This Year?

Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program

Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.

Calendar of U.S. Earnings Expected in the Week Ahead

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/COYA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"COYA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"COYA\",,,,,undefined,":{"symbol":"COYA","market":"US","secType":"STK","nameCN":"COYA THERAPEUTICS INC","latestPrice":6.28,"timestamp":1746129600000,"preClose":6.59,"halted":0,"volume":40413,"hourTrading":{"tag":"盘后","latestPrice":6.28,"preClose":6.28,"latestTime":"16:09 EDT","volume":31,"amount":206.38,"timestamp":1746130167125},"delay":0,"floatShares":12564296,"shares":16724998,"eps":-0.976498,"marketStatus":"Not Yet Opened","change":-0.31,"latestTime":"05-01 16:00:00 EDT","open":6.64,"high":6.64,"low":6.2,"amount":255534.1695,"amplitude":0.066768,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.976498,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746172800000},"marketStatusCode":0,"adr":0,"listingDate":1672290000000,"exchange":"NASDAQ","adjPreClose":6.59,"preHourTrading":{"tag":"盘前","latestPrice":6.43,"preClose":6.59,"latestTime":"08:29 EDT","volume":402,"amount":2546.159862,"timestamp":1746102575519},"postHourTrading":{"tag":"盘后","latestPrice":6.28,"preClose":6.28,"latestTime":"16:09 EDT","volume":31,"amount":206.38,"timestamp":1746130167125},"volumeRatio":0.848895},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"COYA\",,,,,undefined,":{"symbol":"COYA","floatShares":12564296,"roa":"-25.15%","roe":"-39.57%","lyrEps":-0.976498,"volumeRatio":0.848895,"shares":16724998,"dividePrice":0,"high":6.64,"amplitude":0.066768,"preClose":6.59,"low":6.2,"week52Low":4.65,"pbRate":"2.65","psRate":"29.55","week52High":10.24,"institutionHeld":0,"latestPrice":6.28,"eps":-0.976498,"divideRate":0,"volume":40413,"delay":0,"ttmEps":-0.976498,"open":6.64,"prevYearClose":5.73,"prevWeekClose":6.18,"prevMonthClose":6.59,"prevQuarterClose":6.47,"fiveDayClose":6.53,"twentyDayClose":6.54,"sixtyDayClose":6.22},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"COYA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529772936","title":"Coya Therapeutics Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2529772936","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529772936?lang=en_us&edition=fundamental","pubTime":"2025-04-24 21:54","pubTimestamp":1745502840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/COYA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 24, 2025 09:54 ET (13:54 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COYA","LENZ"],"gpt_icon":0},{"id":"2529989937","title":"Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study With Low-Dose Il-2 and Ctla4-Ig Combination Treatment in Five Patients With Mild to Moderate Frontotemporal Dementia","url":"https://stock-news.laohu8.com/highlight/detail?id=2529989937","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529989937?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:15","pubTimestamp":1745496900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nTUA92PTDK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["COYA","BK4139"],"gpt_icon":0},{"id":"2529398993","title":"Coya Therapeutics Inc - Study Shows Significant Increase in Treg Numbers and Function","url":"https://stock-news.laohu8.com/highlight/detail?id=2529398993","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529398993?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:15","pubTimestamp":1745496900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nTUA92PTDK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["COYA","BK4139"],"gpt_icon":0},{"id":"2529298993","title":"Coya Therapeutics Inc - Ftd Patients Show Minimal to No Cognitive Decline in Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2529298993","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529298993?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:15","pubTimestamp":1745496900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nTUA92PTDK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["COYA","BK4139"],"gpt_icon":0},{"id":"2529981873","title":"Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia","url":"https://stock-news.laohu8.com/highlight/detail?id=2529981873","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529981873?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:15","pubTimestamp":1745496900,"startTime":"0","endTime":"0","summary":"Results from the first patient cohort (N=5) of an open-label proof of concept academic study with low-dose IL-2 and CTLA4-Ig demonstrated a rapid and durable statistically significant increase in the number and suppressive function of Tregs compared to baseline values.Clinically, patients with Frontotemporal Dementia  demonstrated minimal to no cognitive decline throughout the study period. Treatment was well tolerated, no serious adverse events were reported, and all 5 patients completed the study.Dr. Arun Swaminathan, Coya’s Chief Executive Officer followed: \"The results thus far are consistent with previously published encouraging data from an open-label investigator-initiated study of patients with ALS treated with low-dose IL-2/CTLA4-Ig. This interim data in FTD provides us further confidence of our approach to target and enhance Treg biology to address devastating neurodegenerative diseases including ALS and FTD.\". Previous biomarker data presented by the Company demonstrated tha","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/coya-therapeutics-announces-positive-interim-121500327.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["COYA","BK4139","PASS","BK4007","LENZ"],"gpt_icon":0},{"id":"2529965195","title":"Wall Street Analysts See a 144.73% Upside in Coya Therapeutics, Inc. (COYA): Can the Stock Really Move This High?","url":"https://stock-news.laohu8.com/highlight/detail?id=2529965195","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529965195?lang=en_us&edition=fundamental","pubTime":"2025-04-23 21:55","pubTimestamp":1745416504,"startTime":"0","endTime":"0","summary":"Coya Therapeutics, Inc.  closed the last trading session at $6.64, gaining 1.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $16.25 indicates a 144.7% upside potential.The mean estimate comprises four short-term price targets with a standard deviation of $2.06. While the lowest estimate of $14 indicates an 110.8% increase from the current price level, the most optimistic analyst expects the stock to surge 171.1% to reach $18. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.However, an impressive consensus price target is not the only factor that indicates a potential upside in COYA. This view is strengthened by the agreement among analysts that the company will report better earnings than what they estimated earlier.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/wall-street-analysts-see-144-135504141.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","COYA"],"gpt_icon":0},{"id":"2529807540","title":"Coya Therapeutics announces publication of study results on COYA 303","url":"https://stock-news.laohu8.com/highlight/detail?id=2529807540","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529807540?lang=en_us&edition=fundamental","pubTime":"2025-04-21 21:55","pubTimestamp":1745243710,"startTime":"0","endTime":"0","summary":"Coya Therapeutics (COYA) announced publication of the results of a study designed to evaluate the effects of COYA 303, Coya’s investigational biolo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/coya-therapeutics-announces-publication-of-study-results-on-coya-303?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/coya-therapeutics-announces-publication-of-study-results-on-coya-303?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["COYA","BK4139"],"gpt_icon":0},{"id":"2529802401","title":"Coya Therapeutics Announces Publication of Glp-1/Ld Il-2 Combination Biologic (Coya 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)","url":"https://stock-news.laohu8.com/highlight/detail?id=2529802401","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529802401?lang=en_us&edition=fundamental","pubTime":"2025-04-21 21:51","pubTimestamp":1745243460,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nTUA8MNVJH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","COYA"],"gpt_icon":0},{"id":"2529807972","title":"Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)","url":"https://stock-news.laohu8.com/highlight/detail?id=2529807972","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529807972?lang=en_us&edition=fundamental","pubTime":"2025-04-21 21:51","pubTimestamp":1745243460,"startTime":"0","endTime":"0","summary":"COYA 303 is an investigational biologic combination of COYA 301, Coya’s low-dose interleukin 2  and a GLP-1 receptor agonist , designed to deliver a multi-targeted immunomodulatory therapeutic in autoimmune and neurodegenerative diseases. COYA 303 produced a statistically significantly higher Treg suppressive effect on pro-inflammatory myeloid cells and enhanced Treg survival in in vitro human immune cells, compared to the individual components - LD IL-2 and GLP-1RA. Dr. Fred Grossman, Coya’s Chief Medical Officer commented, \"We believe the encouraging results of this study provide support for our multi-targeted combination approach as a potentially viable treatment option for serious and life-threatening conditions of high unmet need driven by chronic inflammation and Treg dysfunction, for which currently av","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/coya-therapeutics-announces-publication-glp-135100483.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LD","COYA","GLP"],"gpt_icon":0},{"id":"2528179095","title":"BRIEF-Atea Pharmaceuticals Appoints Howard H. Berman To Board Of Directors And Announces Share Repurchase Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2528179095","media":"Reuters","labels":["executive","shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528179095?lang=en_us&edition=fundamental","pubTime":"2025-04-17 19:05","pubTimestamp":1744887914,"startTime":"0","endTime":"0","summary":"BRIEF-Atea Pharmaceuticals Appoints Howard H. Berman To Board Of Directors And Announces Share Repurchase ProgramApril 17 (Reuters) - Atea Pharmaceuticals Inc AVIR.O:ATEA PHARMACEUTICALS APPOINTS HOWA","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nTUA47GFRM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVIR","BK4139","COYA","BK4007"],"gpt_icon":0},{"id":"2528797011","title":"Atea Pharmaceuticals Inc: Authorized Repurchase of up to $25 Mln of Company's Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2528797011","media":"THOMSON REUTERS","labels":["buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528797011?lang=en_us&edition=fundamental","pubTime":"2025-04-17 19:00","pubTimestamp":1744887601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nTUA47GFRM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVIR","BK4139","COYA","BK4007"],"gpt_icon":0},{"id":"2528179709","title":"Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2528179709","media":"THOMSON REUTERS","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528179709?lang=en_us&edition=fundamental","pubTime":"2025-04-17 19:00","pubTimestamp":1744887601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nTUA47GFRM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["COYA","BK4007","BK4139","AVIR"],"gpt_icon":0},{"id":"2528797700","title":"Press Release: Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2528797700","media":"Dow Jones","labels":["executive","shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528797700?lang=en_us&edition=fundamental","pubTime":"2025-04-17 19:00","pubTimestamp":1744887600,"startTime":"0","endTime":"0","summary":"Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program. Enters into Agreement with Bradley L. Radoff and Michael Torok. \"We are pleased to welcome Howard Berman to the Atea Board,\" said Jean-Pierre Sommadossi, Ph.D., Chief Executive Officer and Founder of Atea. \"We look forward to benefitting from Dr. Berman's industry experience and insights as we advance our global Phase 3 program evaluating the regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus  and our efforts to deliver value to Atea's shareholders.\". \"Atea's de-risked Phase 3 program with its potential best-in-class profile for the treatment of HCV has the potential to disrupt a multi-billion global market,\" said Dr. Berman. \"I look forward to joining the Board and working with my fellow directors on behalf of all Atea's shareholders.\". Atea also today announced that its Board has authorized, and will promptly begin executing upon, the repurchase of up","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","BK4139","COYA","BK4007","AVIR","HBMD"],"gpt_icon":0},{"id":"2526610865","title":"Is Coya Therapeutics (COYA) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?","url":"https://stock-news.laohu8.com/highlight/detail?id=2526610865","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526610865?lang=en_us&edition=fundamental","pubTime":"2025-04-12 03:02","pubTimestamp":1744398140,"startTime":"0","endTime":"0","summary":"We recently published a list of Top 9 Healthcare Stocks to Buy According to Billionaire David Einhorn. In this article, we are going to take a look at where Coya Therapeutics, Inc.  stands against other top healthcare stocks to buy according to Billionaire David Einhorn.Wall Street has come down crashing on President Donald Trump’s sweeping tariffs, raising the risk of a trade war that could push the global economy into recession. Major equity indexes have recorded their worst days in years, with the S&P 500 slipping back into correction territory. Amid the bloodbath, the focus is slowly turning to defensive sectors poised to shrug off the long-term effects of the trade war.“We have reached the ‘Fartcoin’ stage of the market cycle,” Einhorn wrote in an investor letter obtained by CNBC. “Other than trading and speculation, it serves no other obvious purpose and fulfills no need that is not served elsewhere.”“Within the equity market, we continue to recommend that investors own the healt","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/coya-therapeutics-coya-top-healthcare-190220307.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4504","QLD","USAW.SI","BK4550","IVV","OEX","ESmain","PSQ","BK4585","USJW.SI","SDS","TSYW.SI","BK4559","BK4588","BK4137","NQmain","HCSG","COYA","OEF","SSO",".IXIC","SPY","BK4534","BK4139","VOO","MNQmain","TQQQ",".SPX","NVIW.SI","BK4581","SQQQ","QID","GLRE","SH"],"gpt_icon":1},{"id":"2524011384","title":"Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2524011384","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524011384?lang=en_us&edition=fundamental","pubTime":"2025-04-01 20:15","pubTimestamp":1743509700,"startTime":"0","endTime":"0","summary":"Principal Investigator Alireza Faridar, M.D. to provide overview of data for the investigator-initiated \"Phase II Clinical Trial of Interleukin-2  in Patients with Mild to Moderate Alzheimer’s disease\". HOUSTON, April 01, 2025----Coya Therapeutics, Inc.  , a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell  function, announces that the principal investigator of a low-dose IL-2 Phase 2 study in Alzheimer’s disease , Alireza Faridar, M.D. from Houston Methodist Hospital, will be presenting previously announced progress to date at the ADPD 2025 conference in Vienna.The presentation, titled, \"A Phase II Clinical Trial of Interleukin-2  in Patients with Mild to Moderate Alzheimer’s disease,\" will take place on April 5, 2025.Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but not limited to, those","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/coya-therapeutics-selected-platform-presentation-121500422.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["COYA","LENZ","BK4139"],"gpt_icon":0},{"id":"2522389555","title":"What Makes Coya Therapeutics, Inc. (COYA) a New Buy Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2522389555","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522389555?lang=en_us&edition=fundamental","pubTime":"2025-03-28 00:00","pubTimestamp":1743091210,"startTime":"0","endTime":"0","summary":"Coya Therapeutics, Inc.  could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 . This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Therefore, the Zacks rating upgrade for Coya Therapeutics, Inc. basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.For Coya Therapeutics, Inc. rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher.This company is expected to earn -$1.36 per sh","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/makes-coya-therapeutics-inc-coya-160010576.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["COYA","BK4139"],"gpt_icon":0},{"id":"2522058852","title":"Are Medical Stocks Lagging  Auna S.A. (AUNA) This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2522058852","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522058852?lang=en_us&edition=fundamental","pubTime":"2025-03-27 21:40","pubTimestamp":1743082808,"startTime":"0","endTime":"0","summary":"Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Auna S.A.  been one of those stocks this year?A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Auna S.A. is a member of our Medical group, which includes 1010 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Auna S.A. is currently sporting a Zacks Rank of #2 .One other Medical stock that has outperformed the sector so far this year is Coya Therapeutics,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/medical-stocks-lagging-auna-auna-134008985.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","COYA","BK4185","AUNA"],"gpt_icon":0},{"id":"2522963805","title":"Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2522963805","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522963805?lang=en_us&edition=fundamental","pubTime":"2025-03-26 20:15","pubTimestamp":1742991300,"startTime":"0","endTime":"0","summary":"Regulatory T cell-derived exosomes  have demonstrated strong and consistent therapeutic potential in suppressing inflammation in preclinical models of neurodegenerative diseases as previously published here. Treg exosomes are end-stage differentiated, making them less likely to be affected by pro-inflammatory factors that may impact their suppressive function. The work planned includes GMP processes and manufacturing activities and the production of larger-scale clinical batches in the fourth quarter of 2025, in preparation for a first in human study. Coya’s previous research demonstrated that ex vivo expanded Treg exosomes express key immunoregulatory markers and effectively suppress pro-inflammatory responses in vitro. Treg exosomes are highly suppressive on pro-inflammatory macrophages and responder T cells. Additionally, Treg exosomes have advantages over Tregs in that they are taken up by myeloid cells that drive disease progression, and they are resistant to conversion to a non-s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/coya-therapeutics-reports-progress-academic-121500976.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4139","COYA","LU2065732104.USD","PRGS","BK4097"],"gpt_icon":0},{"id":"2520557924","title":"Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2520557924","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520557924?lang=en_us&edition=fundamental","pubTime":"2025-03-20 20:00","pubTimestamp":1742472059,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com?So should Coya Therapeutics  shareholders be worried about its cash burn?For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth . First, we'll determine its cash runway by comparing its cash burn with its cash reserves.Does Coya Therapeutics Have A Long Cash Runway?On this analysis of Coya Therapeutics' cash burn, we think its cash runway was rea","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/coya-therapeutics-nasdaq-coya-good-120059616.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2095319765.USD","QLD","BK4112","USAW.SI","IE00BGHQF748.EUR","PSQ","BK4585","IE00BKPKM429.USD","USJW.SI","TSYW.SI","BK4588","NQmain","COYA",".IXIC","BK4139","LU2210149790.SGD","NDAQ","MNQmain","IE00B64PRP62.GBP","TQQQ","NVIW.SI","SQQQ","IE00B3QW5Z07.USD","QID","LU2210150020.SGD"],"gpt_icon":1},{"id":"2520439968","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2520439968","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520439968?lang=en_us&edition=fundamental","pubTime":"2025-03-20 18:00","pubTimestamp":1742464800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Amprius Tech Inc                                4Q      (.11)  4:05 PM. ·Lands' End Inc.                                   4Q       .57   6:45 AM. ·Lennar Corp Class A                              1Q      1.70       AMC","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMC","TELA","NKTX","DERM","LVTX","MNSO","JEF","NKE","PAYX","FLUX","SPRY","MBRX","JKS","ACRV","KLC","PL","WOR","CURV","GDEV","IFRX","THRD","ALUR","BRNS","CDLR","FBRX","OUST","SLS","RLMD","BCAB","SBS","LEN","MLKN","BBNX","TITN","TH","COYA","MGNX","CBUS","LPTX","MREO","ASO","RUM","DRI","SOWG","BLRX","BRAG","SKYE","CELC"],"gpt_icon":1}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":60,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/COYA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"COYA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"COYA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2,"buy":0.8,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8,"analysts":5,"updateTime":1742875200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/COYA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"COYA","date":"2025-04-30","current":-6.855987,"percent":0.547406,"low":-18.170827,"twenty":-10.333587,"median":-7.477816,"eighty":-3.648113,"high":-2.532969,"avg":-7.448167,"sd":3.878295,"marketCap":102022487},"quantilePoints":[{"date":"2022-12-30","current":-4.259584,"twenty":-5.088378,"median":-4.673981,"eighty":-4.199135,"marketCap":45862003},{"date":"2023-01-06","current":-4.198451,"twenty":-4.75686,"median":-4.211892,"eighty":-4.164199,"marketCap":45203803},{"date":"2023-01-13","current":-4.315322,"twenty":-4.421315,"median":-4.259584,"eighty":-4.180381,"marketCap":46462126},{"date":"2023-01-20","current":-4.288262,"twenty":-4.396143,"median":-4.253021,"eighty":-4.180381,"marketCap":46170776},{"date":"2023-01-27","current":-4.181765,"twenty":-4.394298,"median":-4.256303,"eighty":-4.180658,"marketCap":45024142},{"date":"2023-02-03","current":-3.675163,"twenty":-4.351211,"median":-4.234322,"eighty":-4.117451,"marketCap":39569675},{"date":"2023-02-10","current":-3.877804,"twenty":-4.30991,"median":-4.190108,"eighty":-3.84096,"marketCap":41751462},{"date":"2023-02-17","current":-3.850171,"twenty":-4.288262,"median":-4.180381,"eighty":-3.855698,"marketCap":41453946},{"date":"2023-02-24","current":-3.684374,"twenty":-4.288262,"median":-4.153411,"eighty":-3.785695,"marketCap":39668848},{"date":"2023-03-03","current":-4.089655,"twenty":-4.270282,"median":-4.071233,"eighty":-3.770128,"marketCap":44032421},{"date":"2023-03-10","current":-4.23703,"twenty":-4.288262,"median":-4.153411,"eighty":-3.785695,"marketCap":45619175},{"date":"2023-03-17","current":-3.905437,"twenty":-4.29377,"median":-4.180381,"eighty":-3.822538,"marketCap":42048978},{"date":"2023-03-24","current":-3.73964,"twenty":-4.288262,"median":-4.108461,"eighty":-3.73964,"marketCap":40263880},{"date":"2023-03-31","current":-3.218192,"twenty":-4.288262,"median":-4.048207,"eighty":-3.707402,"marketCap":39406041},{"date":"2023-04-06","current":-3.099387,"twenty":-4.273878,"median":-3.979124,"eighty":-3.684448,"marketCap":37951295},{"date":"2023-04-14","current":-3.233436,"twenty":-4.261724,"median":-3.905437,"eighty":-3.63832,"marketCap":39592701},{"date":"2023-04-21","current":-3.534032,"twenty":-4.256278,"median":-3.877804,"eighty":-3.512909,"marketCap":43273430},{"date":"2023-04-28","current":-3.753386,"twenty":-4.253993,"median":-3.850523,"eighty":-3.541339,"marketCap":45959367},{"date":"2023-05-05","current":-4.053981,"twenty":-4.248953,"median":-3.850876,"eighty":-3.590423,"marketCap":49640095},{"date":"2023-05-12","current":-3.858435,"twenty":-4.25448,"median":-3.877804,"eighty":-3.627267,"marketCap":51231762},{"date":"2023-05-19","current":-4.210564,"twenty":-4.257931,"median":-3.905437,"eighty":-3.63832,"marketCap":55907282},{"date":"2023-05-26","current":-3.109224,"twenty":-4.25448,"median":-3.877804,"eighty":-3.560217,"marketCap":41283847},{"date":"2023-06-02","current":-3.431385,"twenty":-4.251665,"median":-3.850876,"eighty":-3.429011,"marketCap":45561450},{"date":"2023-06-09","current":-3.611196,"twenty":-4.244399,"median":-3.84096,"eighty":-3.421013,"marketCap":47948950},{"date":"2023-06-16","current":-3.618688,"twenty":-4.23703,"median":-3.850171,"eighty":-3.424798,"marketCap":48048429},{"date":"2023-06-23","current":-3.566243,"twenty":-4.23703,"median":-3.830566,"eighty":-3.428417,"marketCap":47352075},{"date":"2023-06-30","current":-3.146685,"twenty":-4.23703,"median":-3.818461,"eighty":-3.418016,"marketCap":41781243},{"date":"2023-07-07","current":-3.071764,"twenty":-4.235405,"median":-3.785695,"eighty":-3.362458,"marketCap":40786451},{"date":"2023-07-14","current":-3.041795,"twenty":-4.228928,"median":-3.76675,"eighty":-3.288681,"marketCap":40388534},{"date":"2023-07-21","current":-2.981859,"twenty":-4.224887,"median":-3.746054,"eighty":-3.233436,"marketCap":39592701},{"date":"2023-07-28","current":-3.019319,"twenty":-4.216174,"median":-3.721218,"eighty":-3.218192,"marketCap":40090097},{"date":"2023-08-04","current":-2.876969,"twenty":-4.203296,"median":-3.712007,"eighty":-3.16841,"marketCap":38199993},{"date":"2023-08-11","current":-2.839996,"twenty":-4.188439,"median":-3.693585,"eighty":-3.145639,"marketCap":36807285},{"date":"2023-08-18","current":-2.54832,"twenty":-4.180935,"median":-3.684466,"eighty":-3.105289,"marketCap":33027077},{"date":"2023-08-25","current":-2.709509,"twenty":-4.180381,"median":-3.675163,"eighty":-3.078507,"marketCap":35116139},{"date":"2023-09-01","current":-2.709509,"twenty":-4.180381,"median":-3.63832,"eighty":-3.046291,"marketCap":35116139},{"date":"2023-09-08","current":-3.691995,"twenty":-4.169593,"median":-3.63832,"eighty":-3.044792,"marketCap":47849471},{"date":"2023-09-15","current":-3.546157,"twenty":-4.135431,"median":-3.63832,"eighty":-3.058278,"marketCap":45959367},{"date":"2023-09-21","current":-3.031887,"twenty":-4.1047,"median":-3.619293,"eighty":-3.053783,"marketCap":39294264},{"date":"2023-09-29","current":-3.162374,"twenty":-4.08252,"median":-3.599887,"eighty":-3.071764,"marketCap":40985409},{"date":"2023-10-06","current":-2.594374,"twenty":-4.053747,"median":-3.556227,"eighty":-3.033869,"marketCap":33623952},{"date":"2023-10-13","current":-3.745724,"twenty":-4.05097,"median":-3.54621,"eighty":-3.041795,"marketCap":48545825},{"date":"2023-10-20","current":-3.937616,"twenty":-4.036232,"median":-3.575206,"eighty":-3.043294,"marketCap":51032803},{"date":"2023-10-27","current":-3.645941,"twenty":-4.021495,"median":-3.590557,"eighty":-3.046291,"marketCap":47252596},{"date":"2023-11-03","current":-3.684319,"twenty":-3.985193,"median":-3.599887,"eighty":-3.062774,"marketCap":47749992},{"date":"2023-11-10","current":-3.870934,"twenty":-4.021495,"median":-3.619293,"eighty":-3.071764,"marketCap":47850465},{"date":"2023-11-17","current":-4.057134,"twenty":-4.055242,"median":-3.63832,"eighty":-3.071764,"marketCap":50152180},{"date":"2023-11-24","current":-4.259991,"twenty":-4.064747,"median":-3.645941,"eighty":-3.07577,"marketCap":52659789},{"date":"2023-12-01","current":-4.324905,"twenty":-4.105159,"median":-3.675163,"eighty":-3.082268,"marketCap":53462223},{"date":"2023-12-08","current":-5.631302,"twenty":-4.180381,"median":-3.684374,"eighty":-3.084048,"marketCap":69611225},{"date":"2023-12-15","current":-7.875233,"twenty":-4.205719,"median":-3.689056,"eighty":-3.088687,"marketCap":97349529},{"date":"2023-12-22","current":-7.933482,"twenty":-4.235947,"median":-3.693585,"eighty":-3.093672,"marketCap":98069570},{"date":"2023-12-29","current":-8.842163,"twenty":-4.23703,"median":-3.709704,"eighty":-3.09424,"marketCap":109302208},{"date":"2024-01-05","current":-7.793685,"twenty":-4.253993,"median":-3.715021,"eighty":-3.09424,"marketCap":96341472},{"date":"2024-01-12","current":-7.877698,"twenty":-4.259991,"median":-3.721218,"eighty":-3.097328,"marketCap":97379997},{"date":"2024-01-19","current":-6.724011,"twenty":-4.272114,"median":-3.742682,"eighty":-3.100019,"marketCap":83118725},{"date":"2024-01-26","current":-6.99204,"twenty":-4.300291,"median":-3.753386,"eighty":-3.10427,"marketCap":86431950},{"date":"2024-02-02","current":-7.213454,"twenty":-4.321125,"median":-3.76675,"eighty":-3.109224,"marketCap":89168961},{"date":"2024-02-09","current":-7.935965,"twenty":-4.359055,"median":-3.785695,"eighty":-3.121212,"marketCap":98100263},{"date":"2024-02-16","current":-8.91485,"twenty":-4.404211,"median":-3.812795,"eighty":-3.139255,"marketCap":110200736},{"date":"2024-02-23","current":-10.04523,"twenty":-4.438913,"median":-3.822509,"eighty":-3.140292,"marketCap":124173901},{"date":"2024-03-01","current":-10.476406,"twenty":-5.628056,"median":-3.830566,"eighty":-3.144593,"marketCap":129503871},{"date":"2024-03-08","current":-10.441446,"twenty":-5.900696,"median":-3.837832,"eighty":-3.146685,"marketCap":129071712},{"date":"2024-03-15","current":-11.653399,"twenty":-6.72168,"median":-3.850171,"eighty":-3.146685,"marketCap":144053250},{"date":"2024-03-22","current":-18.042053,"twenty":-6.870845,"median":-3.854655,"eighty":-3.146752,"marketCap":144116957},{"date":"2024-03-28","current":-17.568699,"twenty":-6.99204,"median":-3.858435,"eighty":-3.147022,"marketCap":140335887},{"date":"2024-04-05","current":-16.744948,"twenty":-7.213454,"median":-3.877804,"eighty":-3.154698,"marketCap":133755895},{"date":"2024-04-12","current":-16.708387,"twenty":-7.481482,"median":-3.895399,"eighty":-3.162374,"marketCap":133463852},{"date":"2024-04-19","current":-15.428751,"twenty":-7.933482,"median":-3.905437,"eighty":-3.168361,"marketCap":123242331},{"date":"2024-04-26","current":-15.41047,"twenty":-7.947618,"median":-3.91531,"eighty":-3.168442,"marketCap":123096309},{"date":"2024-05-03","current":-16.050288,"twenty":-8.108228,"median":-3.925864,"eighty":-3.184145,"marketCap":128207070},{"date":"2024-05-10","current":-15.465312,"twenty":-8.157379,"median":-3.945867,"eighty":-3.193076,"marketCap":123534375},{"date":"2024-05-17","current":-12.046492,"twenty":-8.434421,"median":-4.006757,"eighty":-3.19913,"marketCap":124118462},{"date":"2024-05-24","current":-12.027546,"twenty":-8.842163,"median":-4.037702,"eighty":-3.208428,"marketCap":123923260},{"date":"2024-05-31","current":-11.153807,"twenty":-9.523158,"median":-4.053396,"eighty":-3.216239,"marketCap":114920875},{"date":"2024-06-07","current":-10.311731,"twenty":-10.30363,"median":-4.063993,"eighty":-3.218192,"marketCap":106244729},{"date":"2024-06-14","current":-11.493592,"twenty":-10.481448,"median":-4.089655,"eighty":-3.221544,"marketCap":118421776},{"date":"2024-06-21","current":-9.425336,"twenty":-10.483969,"median":-4.100207,"eighty":-3.22689,"marketCap":97111945},{"date":"2024-06-28","current":-8.996912,"twenty":-10.491151,"median":-4.108461,"eighty":-3.230001,"marketCap":92697765},{"date":"2024-07-05","current":-8.819633,"twenty":-10.481448,"median":-4.153411,"eighty":-3.232684,"marketCap":90871208},{"date":"2024-07-12","current":-10.592423,"twenty":-10.481448,"median":-4.180381,"eighty":-3.233436,"marketCap":109136778},{"date":"2024-07-15","current":-11.065167,"twenty":-10.491151,"median":-4.180381,"eighty":-3.233436,"marketCap":114007596},{"date":"2024-08-02","current":-9.957173,"twenty":-10.489011,"median":-4.181073,"eighty":-3.233436,"marketCap":102591615},{"date":"2024-08-09","current":-9.277604,"twenty":-10.476406,"median":-4.210564,"eighty":-3.233436,"marketCap":95589814},{"date":"2024-08-16","current":-7.550677,"twenty":-10.441446,"median":-4.229827,"eighty":-3.251575,"marketCap":76258753},{"date":"2024-08-23","current":-9.374293,"twenty":-10.311731,"median":-4.23703,"eighty":-3.274051,"marketCap":94676535},{"date":"2024-08-30","current":-8.852829,"twenty":-10.301605,"median":-4.249631,"eighty":-3.28015,"marketCap":89409963},{"date":"2024-09-06","current":-9.133154,"twenty":-10.286069,"median":-4.257518,"eighty":-3.290318,"marketCap":92241126},{"date":"2024-09-13","current":-8.982442,"twenty":-10.167203,"median":-4.259991,"eighty":-3.294066,"marketCap":90718995},{"date":"2024-09-20","current":-9.374293,"twenty":-10.063875,"median":-4.267746,"eighty":-3.325565,"marketCap":94676535},{"date":"2024-09-27","current":-9.46472,"twenty":-10.033878,"median":-4.288262,"eighty":-3.333863,"marketCap":95589814},{"date":"2024-10-04","current":-10.301173,"twenty":-10.081747,"median":-4.299205,"eighty":-3.345975,"marketCap":104037640},{"date":"2024-10-11","current":-10.45942,"twenty":-10.301259,"median":-4.315322,"eighty":-3.366953,"marketCap":105635877},{"date":"2024-10-18","current":-12.388535,"twenty":-10.462817,"median":-4.33302,"eighty":-3.382641,"marketCap":125119151},{"date":"2024-10-25","current":-14.93557,"twenty":-10.558363,"median":-4.357362,"eighty":-3.391203,"marketCap":150843162},{"date":"2024-10-31","current":-10.029891,"twenty":-10.623264,"median":-4.367898,"eighty":-3.402403,"marketCap":101297804},{"date":"2024-11-08","current":-10.271752,"twenty":-10.614867,"median":-4.40398,"eighty":-3.415739,"marketCap":109897843},{"date":"2024-11-15","current":-9.688453,"twenty":-10.599507,"median":-4.432103,"eighty":-3.422453,"marketCap":103657107},{"date":"2024-11-22","current":-9.494429,"twenty":-10.566878,"median":-5.088378,"eighty":-3.426607,"marketCap":101581241},{"date":"2024-11-29","current":-10.181526,"twenty":-10.529794,"median":-5.623188,"eighty":-3.429604,"marketCap":108932515},{"date":"2024-12-06","current":-9.338271,"twenty":-10.495432,"median":-5.858502,"eighty":-3.46435,"marketCap":99910497},{"date":"2024-12-13","current":-9.088417,"twenty":-10.483969,"median":-5.907187,"eighty":-3.516795,"marketCap":97237306},{"date":"2024-12-20","current":-8.057772,"twenty":-10.469612,"median":-6.712358,"eighty":-3.52129,"marketCap":86210395},{"date":"2024-12-27","current":-8.541863,"twenty":-10.455825,"median":-6.793932,"eighty":-3.523838,"marketCap":91389702},{"date":"2025-01-03","current":-8.916643,"twenty":-10.441446,"median":-6.852199,"eighty":-3.534032,"marketCap":95399488},{"date":"2025-01-10","current":-9.478813,"twenty":-10.430887,"median":-6.957079,"eighty":-3.543732,"marketCap":101414166},{"date":"2025-01-17","current":-8.744869,"twenty":-10.348577,"median":-6.99204,"eighty":-3.546199,"marketCap":93561669},{"date":"2025-01-24","current":-9.119649,"twenty":-10.325731,"median":-7.13188,"eighty":-3.555389,"marketCap":97571455},{"date":"2025-01-31","current":-9.150881,"twenty":-10.318171,"median":-7.256788,"eighty":-3.564349,"marketCap":97905604},{"date":"2025-02-07","current":-10.931086,"twenty":-10.318171,"median":-7.341641,"eighty":-3.568008,"marketCap":116952087},{"date":"2025-02-14","current":-10.681233,"twenty":-10.383279,"median":-7.550677,"eighty":-3.569184,"marketCap":114278896},{"date":"2025-02-21","current":-9.634972,"twenty":-10.398268,"median":-7.746602,"eighty":-3.574001,"marketCap":103084910},{"date":"2025-02-28","current":-10.509459,"twenty":-10.398268,"median":-7.876466,"eighty":-3.588691,"marketCap":112441077},{"date":"2025-03-07","current":-9.822362,"twenty":-10.45223,"median":-7.935965,"eighty":-3.604411,"marketCap":105089803},{"date":"2025-03-14","current":-10.119063,"twenty":-10.461335,"median":-7.947618,"eighty":-3.614193,"marketCap":108264217},{"date":"2025-03-21","current":-7.264209,"twenty":-10.461335,"median":-7.947618,"eighty":-3.619172,"marketCap":108097143},{"date":"2025-03-28","current":-7.743894,"twenty":-10.45223,"median":-7.935965,"eighty":-3.621104,"marketCap":115235236},{"date":"2025-04-04","current":-6.855987,"twenty":-10.436166,"median":-7.877698,"eighty":-3.629076,"marketCap":102022487},{"date":"2025-04-11","current":-5.540987,"twenty":-10.398268,"median":-7.770143,"eighty":-3.63832,"marketCap":82454240},{"date":"2025-04-17","current":-5.866927,"twenty":-10.3533,"median":-7.730177,"eighty":-3.639844,"marketCap":87304489},{"date":"2025-04-25","current":-7.339278,"twenty":-10.348372,"median":-7.507868,"eighty":-3.646484,"marketCap":109214236},{"date":"2025-04-30","current":-6.855987,"twenty":-10.333587,"median":-7.477816,"eighty":-3.648113,"marketCap":102022487}],"updateTime":1746123273637}}}